Targeted Therapy for Breast Cancer: — How Biomarker-Driven Treatment Works

Targeted therapy is a group of medicines that act on a specific molecular feature of cancer cells — a surface protein, a hormone receptor, a growth signal or an inherited genetic weakness — rather than attacking every fast-dividing cell the way chemotherapy does. Because they aim at a defined target, these drugs tend to spare most healthy cells, often giving them a different side-effect profile. The key point is that targeted therapy only works when the matching target is present, so treatment begins with biomarker testing of your biopsy — HER2 status, hormone-receptor status and, where relevant, BRCA testing. Targeted therapy is usually combined with, not a replacement for, surgery, radiation, chemotherapy or hormone therapy.

It helps to think in terms of classes. HER2-targeted therapy uses anti-HER2 antibodies to block the HER2 protein in HER2-positive cancers, and combined with chemotherapy it transformed that subtype's outlook. CDK4/6 inhibitors are tablets that block the cell-cycle machinery and are given with hormone therapy for hormone-receptor-positive, HER2-negative cancers. PARP inhibitors are tablets for people with an inherited BRCA mutation, exploiting a repair weakness in those cancer cells. Antibody-drug conjugates deliver a chemotherapy payload directly to cancer cells, and checkpoint immunotherapy helps the immune system attack the tumour — both used for selected, biomarker-defined cancers. Which class can help you depends entirely on your test results.

You do not guess — you test. The same biopsy used to diagnose your cancer is examined for the biomarkers that decide which targeted drugs can help. HER2 testing (by immunohistochemistry, with confirmatory testing if borderline) identifies who can receive HER2-targeted therapy. Hormone-receptor (ER/PR) testing identifies the group eligible for hormone therapy and often CDK4/6 inhibitors. A BRCA genetic test — done on blood or saliva — can make PARP-inhibitor treatment possible. For some advanced cancers, extra markers such as PD-L1 are tested to match immunotherapy. Getting this testing complete and correctly interpreted is the foundation of precise treatment, which is why an accurate pathology report and a tumour board review matter so much.

No. Chemotherapy attacks all rapidly dividing cells in the body, while targeted therapy acts on a specific feature of the cancer cell. Because targeted drugs spare most healthy cells, their side effects are often different from — and in some cases gentler than — chemotherapy, though each class has its own things to monitor, such as heart function or low blood counts. Importantly, targeted therapy usually does not replace chemotherapy. In many subtypes the strongest results come from using them together: HER2-targeted therapy combined with chemotherapy, or CDK4/6 inhibitors combined with hormone therapy. Targeted treatments and hormone therapy are also often taken for months or years, whereas a course of chemotherapy is usually finished within a few months.

Most can, but the options differ by subtype. HER2-positive cancers are treated with HER2-targeted therapy alongside chemotherapy, with further anti-HER2 options for higher-risk or recurrent disease. Hormone-receptor-positive, HER2-negative cancers — the largest group — are treated with hormone therapy, and CDK4/6 inhibitors are added in many cases. Triple-negative breast cancer has no hormone or HER2 target, but checkpoint immunotherapy, PARP inhibitors (for BRCA carriers) and antibody-drug conjugates have all expanded its options. And across every subtype, people with an inherited BRCA mutation may be eligible for PARP-inhibitor tablets. This is why subtyping and complete biomarker testing are always the first step in planning treatment.

Each class has its own pattern, generally different from chemotherapy. HER2-targeted therapy is usually well tolerated but the heart is monitored because it can affect heart function. CDK4/6 inhibitors most often lower white blood cells, watched with blood tests, and can cause tiredness or digestive upset. PARP-inhibitor tablets may cause nausea, tiredness and lower blood counts. Checkpoint immunotherapy can cause immune-related effects that are watched closely, and antibody-drug conjugates carry chemo-like effects because they deliver a chemo payload. Most of these are manageable with monitoring, supportive care and dose adjustments, and many people continue daily life during treatment. Reporting symptoms early is the best way to keep treatment safe and on schedule.

Targeted therapies are among the more expensive cancer treatments, and the cost varies a great deal by class, by how long the treatment runs, and by whether lower-cost biosimilar versions are available — so an honest answer is that it depends on your specific plan rather than a single figure. Several routes can make it more affordable: many health insurance policies cover targeted therapy, eligible patients may be covered under government schemes such as Aarogyasri or Ayushman Bharat, and some manufacturers run patient-access programmes. At CION, we discuss likely costs before treatment starts, help with insurance pre-authorisation and paperwork, offer up to 50% discounts on diagnostics, and never recommend a targeted drug your biomarkers do not support.

Yes. CION offers a free first consultation for all cancer patients, including women who want to know whether targeted therapy is an option or who are seeking a second opinion. It is a full 45-minute consultation — a specialist reviews your biopsy, HER2, hormone-receptor and BRCA results, and explains which targeted treatments your cancer may be eligible for and how they fit with the rest of your plan. Because every decision is reviewed by a tumour board of 3+ oncologists, you can be confident the treatment is matched to your biomarkers, not chosen by guesswork. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.